More frequent seizures during the menstrual cycle in women with genetic generalized epilepsy have been linked for the first time to drug-resistant epilepsy, when anti-seizure medications don't work, ...

An FDA-cleared wrist-worn device reliably detects convulsive seizures in epilepsy monitoring units but can miss focal ...

MOUNTAIN VIEW, Calif., December 08, 2025--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, announced the ...

New Brunswick, N.J. (October 28, 2021) – Combining electroencephalogram (EEG) data with clinical observations can help doctors to better determine whether generalized epilepsy patients will respond to ...

TOKYO, May 13, 2024 - (JCN Newswire) - - Eisai Co., Ltd. announced today that it has received approval in China for the additional indication of its in-house discovered antiepileptic drug (AED) ...

NASHVILLE, Tennessee ―The retention rate for the antiseizure drug perampanel (Eisai Co, Ltd) is more than 70% for adult patients with epilepsy, new research shows. In early results from the PERPRISE ...

People with generalized epilepsy who have seizures arising from both sides of the brain simultaneously, have a higher risk of obstructive sleep apnea (OSA) compared to patients who have focal epilepsy ...

-- New approval for VIMPAT® (lacosamide) CV in the U.S. as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS) in patients four years of age and older -- All three ...

Valproate (Depakene) emerged as the best first-line choice for generalized epilepsy in a pragmatic study and lamotrigine (Lamictal) as the best first-line treatment for focal epilepsy, British ...

More than 3.4 million people in the United States have epilepsy, so it is a relatively common diagnosis. In fact, it is the fourth-most common neurologic condition in the world. November is National ...